Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Phase 2 Completed 26 enrolled Georgetown University Alzheimer's Association · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the effect of Bosutinib (Bosulif,Pfizer®) in the treatment of patients with Dementia with Lewy Bodies. Half participants will receive 100 mg of Bosutinib , while the other half will receive placebo.

Timeline

Start: 2019-04-23
Primary completion: 2021-08-27
Completion: 2021-08-27

Publications

Results Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, Moussa CE. Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in alpha-Synucleinopathy. J Clin Cell Immunol. 2014 Sep 30;5:259. doi: 10.4172/2155-9899.1000259.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Bosutinib	Small molecule	100 mg	Oral
Comparator	Bosutinib	Small molecule	200 mg	Oral

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

Summary

Timeline

Publications

Drugs

Indications